Thryv Therapeutics
PrivateLast Round
Series B
Sep 17, 2025
Total Funding Raised
$40.39M
Momentum Score
25 /100
Company Overview
Thryv Therapeutics is a biotechnology company pioneering a precision medicine approach to treat Long QT Syndrome, heart failure, and atrial fibrillation with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase (SGK1).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Thryv Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Thryv Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 17, 2025 | ||||
| Convertible Debt | Jun 6, 2023 | ||||
| Series A Extension | Jul 11, 2022 | ||||
| Series A | Aug 10, 2021 | ||||
| Seed | Jan 8, 2020 |
Thryv Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Amzak Health | Series A |
| CTI Life Sciences Fund | Series B |
| Amplitude Ventures | Series B, Series A |
| Investissement Québec | Series B, Convertible Debt |
| Fonds de solidarité FTQ | Series A, Series B, Seed |
| Alexandria Venture Investments | Series A |
| Lumira Ventures | Series A, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 22, 2026
Drug candidate THRV-1268 designated for Long QT Syndrome treatment.
- Apr 22, 2026
Patient dosing started for THRV-1268 in Wave II study for Long QT Syndrome.
Thryv Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Thryv Therapeutics's valuation, stock price, and market status.
